Befotertinib was shown to be superior to the first-generation EGFR-inhibitor icotinib in metastatic NSCLC in the phase 3 NCT04206072 trial.782 Other EGFR-inhibitors, such as limertinib, abivertinib, rezivertinib and sunvozertinib have been tested in metastatic NSCLC and demonstrated promising efficacy and tolerable safety profile.783–787 However, phase 3 trials are required to further assess efficacy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.